Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis

LIU Guodong; ZHOU Li; ZHANG Wenjing; WANG Zhuo

doi:10.3969/j.issn.1006-0111.2018.02.019

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To observe the effectiveness and safeness of granulocyte macrophage colony stimulating factor(GM-CSF) and whole lung lavage therapy for patients with idiopathic pulmonary alveolar proteinosis (IPAP). Methods Two IPAP patients who were hospitalized in Changhai Hospital from August 2015 to March 2017 were enrolled for the study. Both patients were treated with GM-CSF therapy after whole lung lavage. One patient received GM-CSF by subcutaneous injection and the other by inhalation. Results Both patients' conditions were improved after GM-CSF and whole lung lavage therapy. Conclusion Treatment with subcutaneous injection or inhalation of granulocyte macrophage colony stimulating factor and whole lung lavage is safe and effective for IPAP patients.

Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis

1. No. 477 Hospital of PLA, Xiangyang 441003, China;Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

2. No. 477 Hospital of PLA, Xiangyang 441003, China

3. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

Received Date: 2017-05-29

Rev Recd Date: 2017-12-07

Key words:

pulmonary alveolar proteinosis /
whole lung lavage /
granulocyte macrophage colony stimulating factor /
treatment outcome

Abstract: Objective To observe the effectiveness and safeness of granulocyte macrophage colony stimulating factor(GM-CSF) and whole lung lavage therapy for patients with idiopathic pulmonary alveolar proteinosis (IPAP). Methods Two IPAP patients who were hospitalized in Changhai Hospital from August 2015 to March 2017 were enrolled for the study. Both patients were treated with GM-CSF therapy after whole lung lavage. One patient received GM-CSF by subcutaneous injection and the other by inhalation. Results Both patients' conditions were improved after GM-CSF and whole lung lavage therapy. Conclusion Treatment with subcutaneous injection or inhalation of granulocyte macrophage colony stimulating factor and whole lung lavage is safe and effective for IPAP patients.

HTML

Reference (15)

[1]	Huaringa AJ, Francis WH. Pulmonary alveolar proteinosis:a case report and world literature review[J]. Respirol Case Rep, 2016, 4(6):e00201.
[2]	郭文亮, 曾运祥, 苏柱泉等. 粒细胞-巨噬细胞集落刺激因子雾化吸入治疗自身免疫性肺泡蛋白沉积症一例并文献复习[J]. 中华结核和呼吸杂志, 2015, 38(10):751-755.
[3]	Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis[J]. Science, 1994, 264(5159):713-716.
[4]	Stanley E, Lieschke G J, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology[J]. Proc Natl Acad Sci U S A, 1994, 91(12):5592-5596.
[5]	Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal[J]. Immunity, 1995, 2(3):211-222.
[6]	Griese M. Pulmonary alveolar proteinosis:a comprehensive clinical perspective[J]. Pediatrics,2017,140(2):e20170610.
[7]	卢惠伦, 罗益锋. 体外膜肺氧合下行全肺大容量灌洗治疗肺泡蛋白沉积症1例并文献复习[J]. 现代医院, 2010, 10(3):13-14.
[8]	Xu Z, Jing J, Wang H, et al. Pulmonary alveolar proteinosis in China:a systematic review of 241 cases[J]. Respirology, 2009, 14(5):761-766.
[9]	赵玉月, 徐作军. 肺泡蛋白沉积症的治疗进展[J]. 中华结核和呼吸杂志, 2014, 37(6):444-447.
[10]	Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis:new insights from a single-center cohort of 70 patients[J]. Respir Med, 2011, 105(12):1908-1916.
[11]	Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis[J]. Am J Respir Crit Care Med, 2001, 163(2):524-531.
[12]	Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis[J]. Chest, 2006, 130(1):227-237.
[13]	Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF[J]. Thorax, 2002, 57(3):277-280.
[14]	Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor:a low toxicity, lung-specific biological therapy in patients with lung metastases[J]. Clin Cancer Res, 1999, 5(9):2316-2323.
[15]	Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis[J]. Am J Respir Crit Care Med, 2010, 181(12):1345-1354.

Message Board

Effectiveness and safeness of granulocyte macrophage colony stimulating factor and whole lung lavage therapy in idiopathic pulmonary alveolar proteinosis

doi: 10.3969/j.issn.1006-0111.2018.02.019

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views